文献速递免疫规划妇幼与学校卫生卫生政策与健康促进

新加坡婴儿RSVpreF母体疫苗预防RSV疾病的成本效果分析

Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for prevention of RSV illness in infants: A cost-effectiveness analysis for Singapore.
PubMed 文献 · Vaccine · 2026-01-30

该研究采用马尔可夫队列模型,从医疗系统视角评估全年RSVpreF母体疫苗接种计划对新加坡婴儿RSV预防的临床与经济影响,并与无干预比较。在人均GDP阈值下,疫苗每剂不超过237.68新加坡元时具有成本效果。

要点

  • 全年RSVpreF母体疫苗接种可减少婴儿RSV相关住院和门诊负担。
  • 在人均GDP阈值下,疫苗每剂≤237.68新加坡元具有成本效果。

核心结论

  • 全年RSVpreF母体疫苗接种有助于减轻新加坡医疗系统压力并降低婴儿RSV临床与经济负担,可能具有成本效果。

研究设计与样本

  • 采用马尔可夫队列模型,从出生至1岁比较RSVpreF疫苗与无干预的临床和经济结局,从医疗系统视角分析,直接成本以2025年新加坡元计,结局按每年3%贴现,并进行情景和敏感性分析。

主要发现

  • 与无干预相比,全年RSVpreF计划在80%覆盖率下每年预防308例住院和1995例门诊就诊。

关键数值与推荐

  • 在每QALY获得阈值1倍人均GDP(121,378新加坡元)下,RSVpreF疫苗每剂价格不超过237.68新加坡元时具有成本效果。

临床怎么用

  • 可为新加坡引入全年RSVpreF母体疫苗接种计划提供成本效果依据,支持在每剂≤237.68新加坡元时实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infections in children. A novel bivalent RSV prefusion F protein subunit (RSVpreF) vaccine has recently been approved by the Health Sciences Authority (HSA) in Singapore. This study estimated the clinical and economic impact of a year-round RSVpreF maternal vaccination program on the prevention of RSV among infants in Singapore. METHODS: A Markov cohort model was used to project clinical and economic outcomes of RSV from birth to one year of age for RSVpreF vaccine compared to no intervention. Analyses were conducted from the healthcare system perspective, with direct costs (2025 Singapore dollars [S$]) and outcomes discounted at 3% annually; scenario and sensitivity analyses tested the robustness of the model. FINDINGS: Compared to no intervention, a year-round RSVpreF program with 80% coverage would prevent 308 hospitalizations and 1995 outpatient visits annually, averting S$2.15 million in direct medical costs and saving 29 quality-adjusted life years (QALYs). The RSVpreF vaccine would be cost-effective up to S$237.68/dose under a cost-effectiveness threshold of 1 x gross domestic product per capita (S$121,378) per QALY gained. INTERPRETATION: Year-round RSVpreF maternal vaccination would help reduce pressures on the healthcare system as well as reduce RSV's clinical and economic burden among infants in Singapore, and likely be a cost-effective program.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Thakkar K, Kefalogianni R, Zhang J, et al. Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for prevention of RSV illness in infants: A cost-effectiveness analysis for Singapore. Vaccine. 2026. PMID: 41619355. doi:10.1016/j.vaccine.2026.128285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。